Obicetrapib Clinical Trials (2026): 18 Studies for High Cholesterol & Hypercholesterolemia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
18 Obicetrapib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 9 indications (including High Cholesterol & Hypercholesterolemia) and 14,305 total planned enrollment. 6 Phase 3 Obicetrapib trials and 7 Phase 2 are listed. 3 Obicetrapib clinical trials are actively recruiting at 22 U.S. sites across 14 states. Most recent activity: NCT07219602 (Jun 2028).
Where to Participate: All Obicetrapib Trial Sites in the U.S. (22 sites across 14 states)
Every actively recruiting Obicetrapibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Clinical Research Institute of Arizona | Sun City West85375 | NCT07219602 | Map |
| CA | Scripps Health - Whittier Diabetes Institute | La Jolla92037 | NCT07219602 | Map |
| FL | East Coast Institute of Research LLC | Jacksonville32216 | NCT07219602 | Map |
| FL | UF Health Jackson | Jacksonville32209 | NCT07219602 | Map |
| FL | East Coast Institute of Research LLC | Lake City32055 | NCT07219602 | Map |
| FL | Excellence Medical Research | Miami Gardens33169 | NCT06982508 | Map |
| FL | Floridian Clinical Research | Miami Lakes33016 | NCT07219602 | Map |
| KY | Louisville Metabolic and Atherosclerosis Research Center (L-MARC) | Louisville40213 | NCT07219602 | Map |
| MD | MD Medical Research | Oxon Hill20745 | NCT07219602 | Map |
| MO | Jefferson City Medical Group | Jefferson City65109 | NCT07219602 | Map |
| MT | Montana Medical Research | Missoula59808 | NCT07219602 | Map |
| NJ | Inspira Health - Internal Medicine Associates | Bridgeton08302 | NCT07219602 | Map |
| NY | Central New York Clinical Research | Manlius13104 | NCT07219602 | Map |
| NC | Velocity Clinical Research | Durham27710 | NCT07219602 | Map |
| NC | Floridian Clinical Research | Greensboro27408 | NCT07219602 | Map |
| NC | Centricity Research dba Lucas Research | Morehead City28557 | NCT07219602 | Map |
| OH | Summit Research Group | Munroe Falls44262 | NCT07219602 | Map |
| PA | UPenn | Philadelphia19104 | NCT06496243 | Map |
| TX | Juno Research LLC - Medical Center | Houston77054 | NCT07219602 | Map |
| TX | Clinical Trials of Texas dba Flourish Research | San Antonio78229 | NCT07219602 | Map |
| VA | Burke Internal Medicine | Burke22015-2234 | NCT07219602 | Map |
| VA | Burke International Medicine DBA Manassas Clinical Research Center | Manassas20110 | NCT07219602 | Map |
Obicetrapib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | Total |
|---|---|---|---|---|
| P1 | 1 | 4 | 5 | |
| P2 | 2 | 5 | 7 | |
| P3 | 1 | 2 | 3 | 6 |
Recruiting Obicetrapib clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07219602 | RUBENSA Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome | P3 | Lipidemia | 300 | Dec 2025 |
| NCT06496243 | VINCENTImpact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | P2 | Dyslipidemias | 69 | Dec 2024 |
| NCT06982508 | VERMEEREvaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers | P2 | Antioxidant Absorption | 100 | Sep 2025 |
Obicetrapib clinical trials by indication
Dyslipidemias (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06496243 | VINCENT | P2 | recruiting | Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels |
| NCT06005597 | TANDEM | P3 | completed | Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies |
| NCT05142722 | BROADWAY | P3 | completed | Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies |
| NCT05425745 | BROOKLYN | P3 | completed | Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. |
| NCT05266586 | ROSE2 | P2 | completed | Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy |
| NCT04753606 | ROSE | P2 | completed | Randomized Study of Obicetrapib as an Adjunct to Statin Therapy |
| NCT04770389 | OCEAN | P2 | completed | Randomized Study of Obicetrapib in Combination With Ezetimibe |
Healthy Volunteers (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06547359 | — | P1 | completed | A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects |
| NCT06250205 | COC | P1 | completed | Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib |
| NCT06081166 | — | P1 | completed | A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin |
Lipidemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07219602 | RUBENS | P3 | recruiting | A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome |
| NCT06305559 | REMBRANDT | P3 | active not recruiting | A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque |
Antioxidant Absorption (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06982508 | VERMEER | P2 | recruiting | Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers |
Lipid Metabolism (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05972278 | — | P1 | active not recruiting | Investigating the Effect of Obicetrapib on Lipoprotein Metabolism |
Hepatic Impairment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06048302 | — | P1 | completed | PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function |
Dyslipidemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05421078 | — | P2 | completed | A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. |
Atherosclerotic Cardiovascular Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05202509 | PREVAIL | P3 | active not recruiting | Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease |
Early Alzheimer's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05161715 | — | P2 | completed | Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease |
Obicetrapib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| RUBENS | NCT07219602 | P3 | recruiting | Lipidemia | 300 | — |
| REMBRANDT | NCT06305559 | P3 | active not recruiting | Lipidemia | 300 | — |
| PREVAIL | NCT05202509 | P3 | active not recruiting | Atherosclerotic Cardiovascular Disease | 9,541 | — |
| TANDEM | NCT06005597 | P3 | completed | Dyslipidemias | 407 | — |
| BROADWAY | NCT05142722 | P3 | completed | Dyslipidemias | 2,530 | — |
| BROOKLYN | NCT05425745 | P3 | completed | Dyslipidemias | 354 | — |
| VINCENT | NCT06496243 | P2 | recruiting | Dyslipidemias | 69 | — |
| VERMEER | NCT06982508 | P2 | recruiting | Antioxidant Absorption | 100 | — |
| ROSE2 | NCT05266586 | P2 | completed | Dyslipidemias | 119 | — |
| ROSE | NCT04753606 | P2 | completed | Dyslipidemias | 120 | — |
| OCEAN | NCT04770389 | P2 | completed | Dyslipidemias | 112 | — |
All Obicetrapib trials (18)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07219602 | RUBENS | A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome | P3 | recruiting | 300 | NewAmsterdam Pharma | Dec 2025 |
| NCT06305559 | REMBRANDT | A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | P3 | active not recruiting | 300 | NewAmsterdam Pharma | May 2024 |
| NCT06496243 | VINCENT | Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | P2 | recruiting | 69 | NewAmsterdam Pharma | Dec 2024 |
| NCT06982508 | VERMEER | Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers | P2 | recruiting | 100 | NewAmsterdam Pharma | Sep 2025 |
| NCT05202509 | PREVAIL | Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | P3 | active not recruiting | 9,541 | NewAmsterdam Pharma | Feb 2022 |
| NCT06547359 | A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects | P1 | completed | 94 | NewAmsterdam Pharma | Oct 2024 | |
| NCT06005597 | TANDEM | Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies | P3 | completed | 407 | NewAmsterdam Pharma | Mar 2024 |
| NCT05972278 | Investigating the Effect of Obicetrapib on Lipoprotein Metabolism | P1 | active not recruiting | 22 | NewAmsterdam Pharma | Dec 2023 | |
| NCT05142722 | BROADWAY | Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies | P3 | completed | 2,530 | NewAmsterdam Pharma | Dec 2021 |
| NCT05425745 | BROOKLYN | Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. | P3 | completed | 354 | NewAmsterdam Pharma | Jul 2022 |
| NCT06250205 | COC | Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib | P1 | completed | 30 | NewAmsterdam Pharma | Feb 2024 |
| NCT06048302 | PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function | P1 | completed | 18 | NewAmsterdam Pharma | Nov 2023 | |
| NCT06081166 | A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin | P1 | completed | 74 | NewAmsterdam Pharma | Nov 2023 | |
| NCT05161715 | Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease | P2 | completed | 13 | NewAmsterdam Pharma | Jan 2022 | |
| NCT05421078 | A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. | P2 | completed | 102 | NewAmsterdam Pharma | Jun 2022 | |
| NCT05266586 | ROSE2 | Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy | P2 | completed | 119 | NewAmsterdam Pharma | Mar 2022 |
| NCT04753606 | ROSE | Randomized Study of Obicetrapib as an Adjunct to Statin Therapy | P2 | completed | 120 | NewAmsterdam Pharma | Feb 2021 |
| NCT04770389 | OCEAN | Randomized Study of Obicetrapib in Combination With Ezetimibe | P2 | completed | 112 | NewAmsterdam Pharma | Feb 2021 |
Obicetrapib clinical trials: frequently asked questions
- How many Obicetrapib clinical trials are there?
- 18 Obicetrapib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 12 are marked completed.
- Are Obicetrapib clinical trials recruiting in 2026?
- Yes — 3 Obicetrapib trials are actively recruiting in 2026, with 22 U.S. sites across 14 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Obicetrapib being studied for?
- Obicetrapib is being studied for High Cholesterol, Hypercholesterolemia, Dyslipidemias, Healthy Volunteers, Familial Hypercholesterolemia and 18 more. The trials are grouped by indication on this page.
- What phase is Obicetrapib in?
- Obicetrapib clinical trials span 6 Phase 3, 7 Phase 2, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Obicetrapib clinical trials?
- The lead sponsor across the most Obicetrapib trials is NewAmsterdam Pharma. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Obicetrapibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: